FC03-04 - Lamotrigine treatment of acute alcohol hallucinosis comorbid depersonalizations disorders: A randomimized double-blind, placebo-controlled study - 05/05/11
Résumé |
Aims |
We compared the efficacy and safety of lamotrigine versus placebo for the treatment of acute alcohol hallucinosis comorbid depersonalization disorders.
Methods |
10 days, randomized, double-blind, parallel study. A total of 40 patients with an ICD-10 diagnosis of acute alcohol hallucinosis comorbid depersonalization disorders were randomized to lamotrigine 300mg/d (n=40), or placebo (n=40). The primary efficacy measure was the PANSS subscale for hallucinosis and Cambridge Depersonalization Scale (CDS).
Results |
Iamotrigine treated patients demonstrated a statistically significant greater improvement in PANSS subscale for hallucinosis and CDS than placebo-treated patients.
Conclusion |
Lamotrigine demonstrated greater efficacy than placebo in treatment of acute hallucinosis comorbid depersonalization disorders and was generally well tolerated.
Le texte complet de cet article est disponible en PDF.
Vol 26 - N° S1
P. 1825 - 2011 Retour au numéro
Article précédent
- FC03-03 - Opiate receptor alleles and alcohol dependence
- S. Kapur, A. Pal
- FC03-05 - An evaluation of service provision by community drug treatment services for opioid dependent pregnant drug users in England and Wales
- R. Perez-Montejano, E. Finch, K. Wolff
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?